MorphoSys AG to be Acquired by Novartis AG Call Transcript

Feb 06, 2024 / 01:00PM GMT

Ladies and gentlemen, welcome to the MorphoSys' Conference Call and Webcast. My name is Anna, and I am your chorus call operator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand to Julia Neugebauer. Please go ahead.

Julia Neugebauer - MorphoSys AG - Head of IR

Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys. And it is my pleasure to welcome you to our conference call today. We will discuss yesterday's announcement of the public takeover offer by Novartis and the sale and transfer of all tafasitamab rights to Incyte.

With me on the call today are Jean-Paul Kress, our Chief Executive Officer; Lucy Crabtree, our Chief Financial Officer; and Charlotte Lohmann, our Chief Legal and Human Resources Officer, will join for the Q&A. Jean-Paul will begin with an overview of the benefits and strategic rationale of the agreements with Novartis and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot